Atrial fibrillation and warfarin use in haemodialysis patients: An individualized holistic approach is important in stroke prevention

Nephrology

Volumn 18, Issue 5, 2013, Pages 331-339

  Thet, Zaw ^a   Vilayur, Eswari ^a,b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

cardiovascular disease; coagulation; haemodialysis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIGOXIN; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; INCIDENCE; META ANALYSIS; PATIENT PREFERENCE; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; SYSTEMATIC REVIEW;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; PREVALENCE; RENAL DIALYSIS; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 84876471062     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12057     Document Type: Review

References (50)

1. Wizemann VTL, Satayathum S, Disney A, et al. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77: 1098-1106.
2. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY,. Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol. 2003; 4: 1.
3. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am. J. Kidney Dis. 2008; 51: 255-262.
4. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int. 2009; 76: 324-330.
5. Abe SYM, Nakanishi N, Yazawa T, Yokota K, Honda M, Sloman G,. Electrocardiographic abnormalities in patients receiving hemodialysis. Am. Heart J. 1996; 131: 1137-1144.
6. Fabbian F, Catalano C, Lambertini D, et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin. Nephrol. 2000; 54: 234-239.
7. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am. Heart J. 2000; 140: 886-890.
8. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am. J. Kidney Dis. 2005; 46: 897-902.
9. Atar I, Konas D, Acikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int. J. Cardiol. 2006; 106: 47-51.
10. To AC, Yehia M, Collins JF,. Atrial fibrillation in haemodialysis patients: Do the guidelines for anticoagulation apply? Nephrology 2007; 12: 441-447.
11. Olesen J, Lip G, Kamper AL, Hommel K, Kober L, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 2012; 367: 625-635.
12. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S,. The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 2011; 22: 349-357.
13. Das M, Aronow WS, McClung JA, Belkin RN,. Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency. Cardiol. Rev. 2006; 14: 14-17.
14. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). (Published erratums appear in Am Heart J 2010; 160: 1190; and in Am Heart J 2011; 162: 794.) Am. Heart J. 2010; 159: 1102-1107.
15. Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 173-181.
16. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998; 32: 107-114.
17. Landray MJ, Wheeler DC, Lip GYH, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am. J. Kidney Dis. 2004; 43: 244-253.
18. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
19. Iguchi Y, Kimura K, Kobayashi K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am. J. Cardiol. 2008; 102: 1056-1059.
20. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am. J. Cardiol. 2003; 92: 868-871.
21. Chan KE, Lazarus JM, Thadhani R, Hakim RM,. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2009; 20: 872-881.
22. US Renal Data System: USRDS 2005/2006/2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. [Cited 2013.] Available from URL: http://www.usrds.org/archive.aspx
23. Chan KE, Lazarus JM, Thadhani R, Hakim RM,. warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 2009; 20: 2223-2233.
24. Gangji AS, Sohal AS, Treleaven D, Crowther MA,. Bleeding in patients with renal insufficiency: A practical guide to clinical management. Thromb. Res. 2006; 118: 423-428.
25. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 705-711.
26. Boccardo P, Remuzzi G, Galbusera M,. Platelet dysfunction in renal failure. Semin. Thromb. Hemost. 2004; 30: 579-589.
27. Kaw D, Malhotra D,. Platelet dysfunction and end-stage renal disease. Semin. Dial. 2006; 19: 317-322.
28. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P,. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am. J. Nephrol. 2001; 21: 35-39.
29. van der Sande FM, Hermans MMH, Leunissen KML, Kooman JP,. Noncardiac consequences of hypertension in hemodialysis patients. Semin. Dial. 2004; 17: 304-306.
30. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T,. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am. J. Kidney Dis. 1998; 31: 991-996.
31. Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am. J. Kidney Dis. 2005; 45: 1058-1066.
32. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO,. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003; 64: 603-609.
33. Kuo C-C, Lee C-T, Ho S-C, Kuo H-W, Wu T-N, Yang C-Y,. Haemodialysis and the risk of stroke: A population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Nephrology 2012; 17: 243-248.
34. Danziger J,. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin. J. Am. Soc. Nephrol. 2008; 3: 1504-1510.
35. Yanagita M,. Gas6, warfarin, and kidney diseases. Clin. Exp. Nephrol. 2004; 8: 304-309.
36. Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J,. Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification quest. Kidney Int. 2009; 76: 18-22.
37. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y,. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol. Dial. Transplant. 2012; 27: 1580-1584.
38. Quinn RR, Naimark DMJ, Oliver MJ, Bayoumi AM,. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am. J. Kidney Dis. 2007; 50: 421-432.
39. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ,. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin. Pharmacol. Ther. 2009; 86: 475-479.
40. Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: Evaluation of recent new drug applications. Clin. Pharmacol. Ther. 2008; 85: 305-311.
41. Ziai F, Benesch Kodras K, Neumann I, Dimpoulos-Xicki L, Hass M,. The effect of oral anticoagulation on clotting during hemodialysis. Kidney Int. 2005; 68: 862-866.
42. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S,. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
43. Miller LM, Hopman WM, Garland JS, Yeates KE, Pilkey RM,. Cardioprotective medication use in hemodialysis patients. Can. J. Cardiol. 2006; 22: 755-760.
44. Elliott MJ, Zimmerman D, Holden RM,. Warfarin anticoagulation in hemodialysis patients: A systematic review of bleeding rates. Am. J. Kidney Dis. 2007; 50: 433-440.
45. Biggers JA, Remmers AR Jr, Glassford DM, Sarles HE, Lindley JD, Fish JC,. The risk of anticoagulation in hemodialysis patients. Nephron 1977; 18: 109-113.
46. Holden RM, Harman GJ, Wang M, Holland D, Day AG,. Major bleeding in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 105-110.
47. Sood P, Sinson GP, Cohen EP,. Subdural hematomas in chronic dialysis patients: Significant and increasing. Clin. J. Am. Soc. Nephrol. 2007; 2: 956-959.
48. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 2006; 151: 713-719.
49. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY,. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100. doi: 1010.1378/chest.1010-0134
50. Lip GY, Frison L, Halperin JL, Lane DA,. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 2011; 57: 173-180. doi: 110.1016/j.jacc.2010.1009.1024